Parnassus Investments LLC Has $49.30 Million Stake in Novo Nordisk A/S $NVO

Parnassus Investments LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 4.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 969,015 shares of the company’s stock after selling 44,669 shares during the period. Parnassus Investments LLC’s holdings in Novo Nordisk A/S were worth $49,303,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Capital International Investors increased its holdings in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares during the period. Franklin Resources Inc. increased its holdings in Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after buying an additional 717,719 shares during the period. State Street Corp increased its holdings in Novo Nordisk A/S by 1.0% in the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after buying an additional 59,153 shares during the period. Boston Partners bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $310,199,000. Finally, Northern Trust Corp increased its holdings in Novo Nordisk A/S by 4.3% in the 3rd quarter. Northern Trust Corp now owns 4,611,126 shares of the company’s stock valued at $255,871,000 after buying an additional 189,640 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a report on Tuesday, March 10th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Wall Street Zen raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Trading Up 2.7%

Shares of Novo Nordisk A/S stock opened at $43.98 on Friday. The firm has a market capitalization of $196.37 billion, a PE ratio of 10.32, a price-to-earnings-growth ratio of 3.83 and a beta of 0.78. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm’s 50 day moving average is $42.13 and its 200 day moving average is $46.01. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Equities research analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Novo Nordisk’s Wegovy pill, making it the first daily GLP-1 weight-loss tablet cleared in the country and opening another major market for the company’s obesity franchise. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Multiple reports highlighted that the approval could strengthen Novo Nordisk’s competitive position versus Eli Lilly by expanding access to an oral alternative to injectable obesity treatments. Novo Nordisk’s Wegovy Weight Loss Pill Approved in the U.K.
• Positive Sentiment: Analyst-style and market commentary noted that Novo Nordisk’s obesity pipeline remains a key growth driver, with recent Phase 3 data for CagriSem adding to enthusiasm around its longer-term GLP-1 strategy. Novo Nordisk (NVO): Top 10 Large Cap Value Stocks to Buy Now
• Neutral Sentiment: Market wrap articles showed NVO outperforming the broader market in recent trading, reflecting renewed investor interest after the regulatory win. Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
• Negative Sentiment: Novo Nordisk also disclosed a cybersecurity incident involving unauthorized access to internal IT systems and possible copying of non-public data, which could weigh on sentiment if the breach proves material. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: A Reuters report said some U.S. employers may drop coverage of GLP-1 obesity drugs in 2027, a potential headwind for future demand growth across the category, including Wegovy. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.